Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Publication ,  Journal Article
Lincoff, AM; Steinhubl, SR; Manoukian, SV; Chew, D; Pollack, CV; Feit, F; Ware, JH; Bertrand, ME; Ohman, EM; Desmet, W; Cox, DA; Mehran, R ...
Published in: Jacc Cardiovasc Interv
December 2008

OBJECTIVES: This study sought to determine if the efficacy of bivalirudin alone versus heparin plus a glycoprotein (GP) IIb/IIIa inhibitor is dependent upon the duration of clopidogrel pre-treatment in patients undergoing percutaneous coronary intervention (PCI) in the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. BACKGROUND: The administration of a clopidogrel loading dose several hours before PCI reduces the risk of periprocedural thrombotic events. METHODS: Patients with an acute coronary syndrome were randomized to heparin plus a GP IIb/IIIa inhibitor (control), bivalirudin plus a GP IIb/IIIa inhibitor, or bivalirudin alone. Dose and timing of clopidogrel were left to the investigator's discretion. RESULTS: Of 13,819 patients randomized, 7,789 underwent PCI. When clopidogrel was initiated at any time before angiography or within 30 min after PCI, randomization to bivalirudin alone (n = 2,284) or control (n = 2,189) was associated with similar ischemic outcomes (8.2% vs. 8.3%, risk ratio: 0.98, 95% confidence interval: 0.81 to 1.20). Those patients who received clopidogrel >30 min after PCI or not at all experienced an increase in ischemic events when randomized to bivalirudin alone (n = 290) versus control (n = 317) (14.1% vs. 8.5%, risk ratio: 1.66, 95% confidence interval: 1.05 to 2.63). Major bleeding was significantly less frequent in patients treated with bivalirudin alone. CONCLUSIONS: This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding. If it is anticipated that clopidogrel will be given late or not at all after PCI, bivalirudin alone may be associated with worse ischemic outcomes. (Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes; NCT00093158).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Jacc Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

December 2008

Volume

1

Issue

6

Start / End Page

639 / 648

Location

United States

Related Subject Headings

  • Young Adult
  • Troponin
  • Treatment Outcome
  • Time Factors
  • Ticlopidine
  • Thrombosis
  • Risk Assessment
  • Recombinant Proteins
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lincoff, A. M., Steinhubl, S. R., Manoukian, S. V., Chew, D., Pollack, C. V., Feit, F., … Acute Catheterization and Urgent Intervention Triage strategY of Trial Investigators, . (2008). Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. Jacc Cardiovasc Interv, 1(6), 639–648. https://doi.org/10.1016/j.jcin.2008.10.004
Lincoff, A Michael, Steven R. Steinhubl, Steven V. Manoukian, Derek Chew, Charles V. Pollack, Frederick Feit, James H. Ware, et al. “Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.Jacc Cardiovasc Interv 1, no. 6 (December 2008): 639–48. https://doi.org/10.1016/j.jcin.2008.10.004.
Lincoff AM, Steinhubl SR, Manoukian SV, Chew D, Pollack CV, Feit F, Ware JH, Bertrand ME, Ohman EM, Desmet W, Cox DA, Mehran R, Stone GW, Acute Catheterization and Urgent Intervention Triage strategY of Trial Investigators. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. Jacc Cardiovasc Interv. 2008 Dec;1(6):639–648.
Journal cover image

Published In

Jacc Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

December 2008

Volume

1

Issue

6

Start / End Page

639 / 648

Location

United States

Related Subject Headings

  • Young Adult
  • Troponin
  • Treatment Outcome
  • Time Factors
  • Ticlopidine
  • Thrombosis
  • Risk Assessment
  • Recombinant Proteins
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors